Guided Therapeutics director exercises 100,000 warrants

Guided Therapeutics Inc. director James Michael C reported warrant exchanges and an exercise involving the company’s common stock.

Rhea-AI Filing Summary

Guided Therapeutics Inc. director James Michael C reported warrant exchanges and an exercise involving the company’s common stock. In February 2026, he exchanged 100,000 warrants with a $0.65 exercise price for 100,000 new warrants with a $0.25 exercise price, then exercised the new warrants for $25,000, receiving 100,000 common shares. As part of the same agreement, the expiration date of separate 4‑year warrants for 100,000 shares with a $0.50 exercise price was extended to September 1, 2027. Following these transactions, he directly held 653,495 common shares and 52,778 warrants.

Insider Trade Summary

100,000 shares exercised/converted

Exercise 6 txns

Insider JAMES MICHAEL C

Role Director

Type	Security	Shares	Price	Value
Other	Warrants	100,000	$0.00	$0.00
Other	Warrants	100,000	$0.00	$0.00
Other	Warrants	100,000	$0.00	$0.00
Other	Warrants	100,000	$0.00	$0.00
In-the-Money Exercise	Warrants	100,000	$0.00	$0.00
In-the-Money Exercise	Common Stock	100,000	$0.00	$0.00

Holdings After Transaction: Warrants — 152,778 contracts (Direct); Common Stock — 653,495 shares (Direct)

Footnotes (1)

1. F1. During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Guided Therapeutics (GTHP) insider James Michael C do in this Form 4?

James Michael C reported exchanging and exercising warrants in Guided Therapeutics. He swapped 100,000 warrants at $0.65 for 100,000 warrants at $0.25, then exercised the new warrants for $25,000 to receive 100,000 common shares and extended other warrants’ expiration.

How many Guided Therapeutics (GTHP) shares did the insider acquire through warrant exercise?

The insider acquired 100,000 Guided Therapeutics common shares through exercising exchanged warrants. These shares came from new warrants with a $0.25 exercise price, exercised for a total payment of $25,000, as disclosed in the footnote to the Form 4 filing.

What warrant exchange terms were disclosed for Guided Therapeutics (GTHP)?

The Form 4 shows an exchange of 100,000 warrants with a $0.65 exercise price for 100,000 new warrants at $0.25. The newly issued warrants were then exercised, and the filing notes these actions occurred during February 2026 under an exchange agreement.

Were any Guided Therapeutics (GTHP) warrant expirations changed in this Form 4?

Yes. The filing states that 4‑year warrants for 100,000 shares with a $0.50 exercise price had their expiration extended by one year, to September 1, 2027, as part of the same exchange agreement described in the Form 4 footnote.

What are James Michael C’s holdings in Guided Therapeutics (GTHP) after these transactions?

After the reported transactions, James Michael C directly held 653,495 Guided Therapeutics common shares and 52,778 warrants. These figures reflect the warrant exchange, subsequent exercise for 100,000 shares, and the remaining derivative securities disclosed in the Form 4.

Did the Guided Therapeutics (GTHP) Form 4 report any open‑market buys or sells?

The Form 4 does not show open‑market buys or sells. It reports warrant exchanges coded as “J” and an in‑the‑money derivative exercise coded as “X,” resulting in 100,000 new common shares and changes to warrant terms and balances.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 03:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JAMES MICHAEL C

(Last) (First) (Middle)

5835 PEACHTREE CORNERS EAST

SUITE B

(Street)

PEACHTREE CORNERS GA 30092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GUIDED THERAPEUTICS INC [ GTHP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		X		100,000	A	(1)	653,495	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$0.5	02/25/2026		J(1)			100,000	09/01/2022	09/01/2026	Common Stock	100,000	(1)	0	D
Warrants	$0.5	02/25/2026		J(1)		100,000		02/25/2026	09/01/2027	Common Stock	100,000	(1)	100,000	D
Warrants	$0.65	02/25/2026		J(1)			100,000	09/01/2022	09/01/2026	Common Stock	100,000	(1)	0	D
Warrants	$0.25	02/25/2026		J(1)		100,000		02/25/2026	02/25/2026	Common Stock	100,000	(1)	152,778	D
Warrants	$0.25	02/25/2026		X			100,000	02/25/2026	02/25/2026	Common Stock	100,000	(1)	52,778	D

Explanation of Responses:

1. During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027.

Remarks:

	/s/ Michael C James	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.